Program
stiripentol
Also written as “Stiripentol”, “Stiripentol Oral Capsule” and “Stiripentol capsule (Diacomit®)”.
Its studies are mostly in Primary hyperoxaluria type 1 · Epilepsies, Myoclonic · Epilepsies, Partial · Hyperoxaluria, Primary, led by Biocodex.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biocodex | 51 open or running | phase 4since May 16, 2022 | Jan 18, 2019 | Aug 2030phase 3 · NCT06465472 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 18, 2019First study: phase 2 study in Hyperoxaluria, PrimaryFirst studyNCT03819647 · 15 enrolled · France
- Mar 5, 2019Phase 1 study in Healthy VolunteersNCT03866928 · 14 enrolled · Belgium
- May 16, 2022Phase 4 study in Pharmacoresistant Focal EpilepsiesNCT05419180 · 52 enrolled · France
- Jun 3, 2024Phase 3 study in Primary hyperoxaluria type 1NCT06465472 · 42 planned · France
- Aug 29, 2025Phase 1 study in Epilepsies, MyoclonicNCT07176832 · 24 enrolled · France
Ahead
- Aug 2030Primary completion: phase 3 study in Primary hyperoxaluria type 1NCT06465472
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07176832Epilepsies, Myoclonic · France | 1 | Completed | Aug 27, 2025 | 24 |
| NCT06465472Primary hyperoxaluria type 1 · France | 3 | Recruiting | Aug 2030 | 42 |
| NCT05419180Pharmacoresistant Focal Epilepsies · France | 4 | Completed | Jun 13, 2024 | 52 |
| NCT03866928Healthy Volunteers · Belgium | 1 | Completed | Apr 5, 2019 | 14 |
| NCT03819647Hyperoxaluria, Primary · France | 2 | Completed | Dec 18, 2020 | 15 |
How it is read
Names in the registry
- “Stiripentol”, 2 entries
- “Stiripentol Oral Capsule”, 1 entry
- “Stiripentol capsule (Diacomit®)”, 1 entry
- “Stiripentol oral suspension (Diacomit®)”, 1 entry
- “stiripentol (Diacomit)”, 1 entry
Conditions, from the studies’ own filings
- Primary hyperoxaluria type 1, 1 study
- Epilepsies, Myoclonic, 1 study
- Epilepsies, Partial, 1 study
- Hyperoxaluria, Primary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.